with

U.S. stocks deepened their comeback on Monday, with the tech-heavy Nasdaq Composite index scoring its best session since May — after nearly slipping into correction territory last week.

But there’s also been far less research into patients with vascular dementia than in Alzheimer’s.

Novo ran two trials: evoke, which assessed Rybelsus in patients with early Alzheimer’s disease, and evoke+, which was expected to enroll about 20% of patients with vascular dementia as well as people with Alzheimer’s and mixed dementia, which is when a patient is diagnosed with more than one type of dementia.

The evoke+ trial appeared to have under-recruited patients with vascular dementia, and Novo said that the drug demonstrated an improvement in Alzheimer’s-related biomarkers.

This is why some dementia experts believe there may still be an opportunity to design better trials that test drugs like GLP-1s in patients with this form of dementia.